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Abstract 
 
Introduction: Antibiotics are commonly associated with hypersensitivity reactions. These can be 
expressed through clinical manifestations that range from mild symptoms to severe life-threating 
reactions. Nevertheless, these are often mistaken with adverse events. Incorrect labelling off a patient as 
allergic, leads to increase in costs and morbidity in the health care setting.  
Objectives: Review currently available information on evaluation, diagnosis and treatment of allergic 
antibiotic reactions. 
Methods: A search was conducted in the PubMed, filtering results to articles published in the last ten 
years, in English, in adults and with full texts available. Out of the eight hundred and twenty-six results, 
seventy-three were selected. 
Results: Diagnosis of allergic events require a detailed anamnesis. Confirmation of the diagnosis is 
influenced by the clinical features and the type of reaction, immediate or nonimmediate. The first can 
be evaluated with skin tests and drug provocation tests. The latter are studied with delayed-reading skin 
tests and drug provocation tests. Management of this patients should follow avoidance and application 
of an alternative tolerated drug. However, if the drug in question is indispensable for the treatment of 
the patient, then desensitization can be tried. 
Discussion: Clinical history is a fundamental component in the management of this patients. Skin tests 
are less well validated to antibiotics other than β-lactam. In vitro tests have not been fully validated in 
large samples of subjects. Desensitization has been validated for patients with β-lactam immediate 
reactions, but further investigation is required for non-immediate reactions, as well as, for non β-lactam 
antimicrobials 
Conclusion: Management of antimicrobial hypersensitivity follows specific considerations in function 
of the type of allergic reaction and antibiotic class. Further investigation regarding immunochemistry 
and validation of diagnostic tests for non β-lactam antibiotics is required. 
Keywords 
Anti-Bacterial agents; hypersensitivity; penicillin; carbapenem; cephalosporin; monobactam; cross-
reactivity; desensitization; skin testing; drug provocation test; 
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Resumo 
 
Introdução: Antibióticos encontram-se frequentemente associados com reacções alérgicas. Estas 
podem expressar-se através de um espectro manifestações clinicas que podem ir desde sintomas ligeiros 
até quadros potencialmente fatais. No entanto, estas são frequentemente confundidas com reacções 
adversas. A classificação errada do doente como alérgico provoca um aumento dos custos e morbilidade 
associados ao seu tratamento. 
Objectivos: Rever a informação actualmente disponível relativamente à avaliação, diagnóstico e 
tratamento de reacções alérgicas a antibióticos. 
Métodos: A pesquisa foi realizada através do Pubmed, selecionando artigos publicados nos últimos dez 
anos, em inglês, em adultos e com texto completo disponível. De oitocentos e vinte e seis resultados, 
setenta e três foram selecionados. 
Resultados: O diagnóstico de reacções alérgicas requere uma anamnese detalhada. Confirmação do 
diagnóstico é influenciada por características clinicas e tipo de reacção, imediata ou tardia. A primeira 
pode ser avaliada através de testes cutâneos e testes de provocação. O segundo tipo pode ser estudada 
através de teste cutâneos de leitura tardia e testes de provocação. No tratamento destes pacientes, deve-
se evitar o fármaco e aplicar um composto alternativo. No entanto, se o fármaco for indespensável, pode 
ser tentada a dessensibilização. 
Discussão: A anamnese é fundamental na abordagem destes pacientes. Testes cutâneos encontram-se 
menos validados em antibióticos não β-lactâmicos. Testes in vitro ainda não foram validados em estudos 
com amostras grandes. Dessensibilização encontra-se validada para pacientes com reacções imediatas a 
β-lactâmicos, sendo necessários mais estudos para as reacções tardias e antibióticos não β-lactâmicos. 
Conclusão: O tratamento de alergia a antibióticos segue considerações especificas em função do tipo de 
alergia e a classe de antibiótico. São necessários mais estudos para validar testes diagnósticos e 
desenvolver o conhecimento da imunoquímica envolvida nas reacções alérgicas a antibióticos não β-
lactâmicos.  
Palavras-Chave 
Antibioticos; Alergia; Penincilina; Carbapenemos; Cefalosporinas; Monobactamos; Reactividade 
cruzada; Dessensibilização; Testes cutâneos; Testes de Provocação  
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Abbreviations 
Acute generalized exanthematous pustulosis – AGEP 
Amoxicillin – AX 
Antigen-presenting cells – APC 
B cell receptors - BCRs 
Basophil activation tests – BAT 
Benzylpenicilloyl-poly-L-lysine – PPL  
Clavulanic acid – CLV 
Drug Provocation Test – DPT  
Drug-induced hypersensitivity syndrome – DRESS 
Human Immunodeficiency virus - HIV 
Intradermal tests -IDT 
Lymphocyte activation tests – LAT 
Lymphocyte transformation tests – LTT  
Major histocompatibility complexes - MHC 
Minor determinant mixture – MDM 
Skin prick tests – SPT 
Stevens Johnson syndrome – SJS 
T cell receptors - TCRs  
Toxic epidermal necrolysis – TEN 
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Introduction 
 
Anti-bacterial drugs not only represent one of the most prescribed pharmaceuticals in the clinical 
practice, but also are one of the major causes of drug allergy reported in epidemiological studies (1). 
Estimates of prevalence of antibiotic allergy are highly variable. For instance, allergy to beta-lactam 
antibiotics constitutes the most usual form of medication allergy, occurring in 8-12% of patients (2, 3). 
Although being one of most prevalent adverse effects of antibiotic use, the term “allergy” is 
frequently misused in clinical practice (4). An allergic reaction as to be immunologically mediated (2). 
Immunological reactions can be divided as immediate and non-immediate (delayed) hypersensitivity 
reactions. Immediate hypersensitivity is IgE-mediated occurring minutes to one hour after exposure to 
the last dose. Non-immediate hypersensitivity is T cell mediated, taking place hours to days after last 
dose administration (1, 5). 
Furthermore, antibiotic allergic reactions can present themselves in a large spectrum of ways, 
possibly affecting a vast variety of organ systems, in variable severity. The most common clinical 
manifestations of antimicrobial allergy are cutaneous (maculopapular skin eruptions, urticaria, and 
pruritus). Nevertheless, antibiotic hypersensitivity can present with organ-specific (e.g. interstitial 
nephritis) and/or systemic symptoms (e.g. anaphylaxis), but also with potentially fatal reactions such as 
Stevens Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) (1, 2). 
Therefore, it is vital for all medical practitioners to be able to correctly evaluate, diagnose and 
treat patients presenting with allergic reactions, and thus reducing the substantial morbidity, mortality 
and increased health care costs associated with this disease. In this regard, this consists on a review on 
currently available information on how to evaluate, diagnose and treat allergic antibiotic reactions.  
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Methods 
 
Published papers associated with this topic were examined using the PubMed data base. PubMed 
has resources covering more than 26 million of published papers from Medline and life science journals, 
being regularly updated with newly content. The online paper search was conducted using the MeSH 
terms: “Anti-Bacterial Agents"[Mesh]) and "Hypersensitivity"[Mesh]. After that, the papers were 
examined and filtered on the following inclusion and exclusion criteria: being “published in English”, 
being “published between 2006 and 2016”, the content referred to “adults of the age 19 or higher” and 
the articles were available in full text through PubMed. This search wielded eight hundred and twenty-
six results. 
From this initial sample, the abstract of every article was analysed and the additional criteria for 
inclusion and exclusion were applied: do not refer to both anti-bacterial agents and hypersensitivity; not 
following the age criteria; do not provide information on evaluation, diagnose or treatment of allergic 
antibiotic reactions; focus of the article on populations with specials considerations, such as cystic 
fibrosis. After examining all these criteria, seventy-three were considered for the elaboration of this 
review. 
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Results 
 
Antibiotics are amongst the most frequent prescribed pharmaceuticals in medical practice, being 
also reported as one of the most common causes of drug allergy reaction (1, 2, 4, 6). Prevalence of 
antibiotic allergy label range between 10-20%, but only 10-20% of these patients have true allergy 
confirmed by allergologic work-up (7-9). Frequently, patient claims that any type of adverse reactions 
constitutes allergic reactions. However, only when a definite immunologic mechanism is established can 
these reactions be classified as allergic (4, 6). Consequently, patient reported history of antibiotic allergy 
is frequently unfounded, leading to the use of alternative, second choice drugs, with negative 
implications regarding cost, safety, duration of inpatient stay, and efficacy of treatment (4, 10).  
Hypersensitivity reactions to antibiotics have been explained by the hapten and pro-hapten 
model. High molecular weight protein drugs ( >800 Dalton) induce hypersensitivy reactions in a similar 
process to the immunological response to foreign antigenic proteins. The pharmaceutical compound is 
recognized and bound by compatible B cell receptors (BCRs) on B cells. However, this interaction is 
not sufficient to induce B cell proliferation and differentiation. For that to occur, interaction between B 
cells with T helper 2 is mandatory. Activation of naive T helper cells bearing T cell receptors (TCRs) 
with appropriate specificity, requires the presentation of the drug by antigen-presenting cells (APC), as 
an antigenic peptide, on the major histocompatibility complexes (MHCs). Interaction between drug 
peptide-presenting B cells with activated T helper cells induces proliferation, differentiation and 
production of drug-specific antibodies (11). 
However, antibiotics are low molecular weight substances (< 800 Dalton) and cannot be 
presented by APC. In order to induce a hypersensitivity reaction these compounds will act as haptens, 
low-molecular weight substances that can covalently bind to carriers such as proteins or polypeptides. 
The subsequently formed drug–protein complex can now be incorporated by APCs, presented on MHC 
molecules and act as immunogenic peptides, that can be recognized by B and T cells, triggering  antibody 
manufacture or T cell differentiation and clonal expansion of different T cell types, responsible for the 
various types of allergic reactions (11). Pro-haptens are compounds that are immunologically inactive 
in their original form, requiring metabolization to form the reactive metabolites involved in the allergic 
reaction. (11)   
The allergic reactions can be classified according to the Coombs and Gell classification system, 
regarding the pathophysiology and immunological mediators, into four types: I (mediated by drug 
specific IgE antibodies), II (cytotoxic), III (mediated by drug specific IgG or IgM antibodies), and IV 
9 
 
(mediated by drug-specific T lymphocytes) (6, 12). Clinically, hypersensitivity reactions are classified 
in functions of the time elapsed between last drug dose administration and symptom onset, into two 
types: immediate or nonimmediate (2, 4, 6). 
Immediate type hypersensitivity occurs within one hour after administration of the drug and are 
type I reactions, causing mast cells degranulation, producing large amounts of vasoactive substances and 
histamine (6, 13). These types of reactions not only are rapidly progressive and potentially lethal, but 
they also have the tendency to become more severe with repeated exposure. Normally, this reaction 
manifest as urticaria, angioedema, conjunctivitis, rhinitis, bronchospasm, gastrointestinal symptoms, 
and anaphylaxis (2, 4, 6, 12, 13) . 
Nonimmediate reactions arise more than one hour after drug administration and include type II 
to IV allergic reactions. Type II reactions result of circulating antibodies (IgG and IgM) binding to the 
surface of circulating blood cells, inducing the destruction of these cells (haemolytic anaemia, 
neutropenia and thrombocytopenia) (6).  On the other hand, Type III reactions occur due to the formation 
of antibody-antigen complexes that precipitate in tissues and activate complement resulting in a variety 
of clinical syndromes including serum sickness and small-vessel vasculitis, potentially affecting any 
organ system. Clinical manifestations may comprise fever, malaise, nausea, vomiting, diarrhea, 
abdominal pain, arthralgias, myalgias, lymphadenopathy, glomerulonephritis and rash. Type IV 
reactions are mediated by T-cell activation and cytokine expression in response to the drug allergen. 
Although the precise role of T-cells is not completely understood, several situations such as exfoliative 
dermatitis, acute generalized exanthematous pustulosis (AGEP), SJS, TEN, immune hepatitis and drug-
induced hypersensitivity syndrome (DRESS) can be included in this category (1, 2, 6). The DRESS 
syndrome is characterized by a severe skin eruption, fever, hematologic abnormalities (eosinophilia or 
atypical lymphocytes), and internal organ involvement. It has a mortality rate of 10%, occurring between 
2–6 weeks after the beginning of a new drug and may last despite drug discontinuation (6, 14). 
Therefore, the clinical features of antibiotic allergy include a broad spectrum of symptoms, 
depending of the type, severity and organ systems affected (2). Also, variables such as the type of drug 
used, disease being treated and immunological state of the patient, influence the organic response of the 
patient (2). 
The clinical management and assessment of antibiotic allergy requires a detailed medical history. 
Differentiating between drug adverse reactions and true allergy is a crucial step in the patient evaluation. 
Information regarding the specific symptom, the time interval between drug administration and the 
appearance of symptoms, as well as the time between clinical symptoms and allergic evaluation, other 
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medication used by the patient and subsequent reactions to related drugs (2, 6). The assessment of these 
patients also includes a physical examination of all the systems that can be implicated in the clinical 
manifestations. Since cutaneous manifestations are the most common symptoms involved in drug 
allergic reactions, the evaluation of this organ system should be emphasised during physical examination 
(15). The absence of a detailed history may lead to an erroneous classification of the patient as allergic, 
leading to higher costs, longer hospital admission and development of resistant microorganisms (2, 5). 
Confirmation of the diagnosis of allergic reaction should be based on in vivo or in vitro allergy 
tests. The tests to apply are chosen taking in consideration the symptoms expressed by the patient and 
clinical classification of the allergic reaction, as immediate or nonimmediate, but also the nature of the 
antibiotic (12). In the case of immediate reactions, this can be evaluated by in vitro tests such as serum-
specific IgE assays and flow cytometric basophil activation tests (BAT), and in vivo by immediate-
reading skin tests (skin prick tests (SPT) and intradermal tests (IDT)) and drug provocation tests (DPTs), 
in some selected patients. On the other hand, nonimmediate reactions are assessed in vitro test such as 
lymphocyte transformation tests (LTT), lymphocyte activation tests (LAT), and enzyme-linked 
immunospot (ELISpot; Millipore, Bedford, Mass) assays for analysis of antigen-specific, cytokine-
producing cells; the in vivo test includes delayed-reading skin prick tests, patch tests, and DPTs (1, 2, 
12). 
It´s important to refer that the in vitro tests have not been fully validated in large samples studies 
(16). Also, the in vivo tests, have been specially more validated to β-lactams, and in an inferior degree 
for the other classes of antibiotics. Therefore, separate considerations must be made regarding β-lactams 
and to non β-lactams antimicrobials (2, 12). 
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β-lactams antimicrobials 
 
The β-lactams antimicrobials are a group of compounds that include four families of chemically 
related substances that share a β-lactam ring: penicillins, cephalosporins, carbapenems and 
monobactams.  
Penicillins are formed by a thiazolidine ring attached to a β-lactam ring that carries a secondary 
amino group side chain (17, 18). This group of antibiotics is almost completely metabolized (over 95%) 
in the organism into benzylpenicilloyl, which quickly combines proteins conjugates and forms antigenic 
haptens. This is known as the major determinant of penicillin allergy and is responsible for the majority 
of allergies. Unmetabolized penicillin and other minor metabolites (penilloate, penicilloate and specific 
metabolite side chain derivatives) can also work as sensitizers, however in a minor significance, and are 
referred to as minor determinants (19). Therefore, it is possible to conclude that cross-reactivity between 
different penicillins can happen if the allergy is induced by a major determinant. However, if the allergic 
reaction is instigated by unique metabolites or side-chain determinants of semisynthetic penicillins, 
cross-reactivity will not occur (6). 
Immediate hypersensitivity 
 
In the case of the suspicion of an immediate hypersensitivity reaction to a penicillin, the first step 
in the confirmation of this diagnose is a skin test (20). Initially, an SPT is performed with the 
administration of benzylpenicilloyl-poly-L-lysine (PPL), minor determinant mixture (MDM) and 
amoxicillin (AX) (20). In 2004 because cessation of production, this test became unavailable. However, 
in 2009 a new company, Diater, initiated the commercialization of a new kit. This new kit contains PPL, 
yet the MDM now only comprises benzylpenicilloate, eliminating benzylpenicillin and benzyl 
penicilloic acid from the classical evaluation (5). Although some concern remains that the elimination 
of this compounds will lead to a reduction of sensitivity in the skin test evaluation, multiple studies 
carried so far have reveal that these two formulations are equivalent (21-23). 
In the PST, a wheal diameter of at least 3 mm in comparison with the negative control supports a positive 
result (24). American centres recommend a wheal diameter of at least 5 mm to increase specificity. If 
these tests are negative at 15 minutes, they are followed by intradermal tests. Increase in wheal size of 
more than 3 mm from the initial bleb with flare is considered positive (5).  
It is important to highlight four considerations. Firstly, the negative predictive value of skin tests is not 
100%. In fact, approximately 1/3 of patients with penicillins allergy will have a negative skin test result 
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(5, 25). These patients require DPT, considered the gold standard test to confirm or exclude IgE-
mediated penicillin allergy. Skin test is used to reduce the number of DPT and possible oral challenge 
reactions (16).  
Secondly, skin test sensitivity is reduced over time and resensitization, conversion to skin test 
positivity, has been reported in patients revaluated after 4 weeks of negative allergological test, 
especially in patients who have experienced immediate reactions (26). Therefore, European guidelines 
recommend that these tests be carried out shortly after reaction and advise revaluating patients who 
experienced immediate reactions to β-lactams and display negative results in the first allergic evaluation, 
including DPTs, after a period of 2-4 weeks (5, 12). 
Thirdly, skin testing can trigger systematic reactions in approximately 1% of all patients and 9% 
in positive skin test patients (27). Therefore, antibiotic skin testing should only be performed by qualified 
professionals, in a space capable to treat potential systemic reactions such as anaphylaxis (28). Also, in 
patients with history of severe allergic reaction patch tests should be performed before skin testing (29). 
In case of patch-test negativity, for intradermal testing, the drug should be initially tested with the highest 
dilution (12). 
Lastly, laboratory investigations serum-specific IgE assays and BAT have a higher specificity 
than skin tests. Nevertheless, their lower sensibility and higher costs make them be considered in selected 
patients, namely in situations of severe anaphylactic risk, contra-indicating DTP, and skin test negative 
(30). 
Non-Immediate hypersensitivity 
 
In the identification of non-immediate antibiotic allergic reactions, a detailed clinical history is 
important, since the variety of the clinical manifestations can mimic the symptoms of infectious or 
autoimmune diseases. Furthermore, these reactions can be associated with a concomitant viral infection, 
such as HIV, cytomegalovirus, human herpes virus 6, or Epstein Barr Virus (20, 31). 
Evaluation of non-immediate hypersensitivity begins with skin test, with the classic penicillin 
reagents, to exclude immediate hypersensitivity. If this tests are negative, a late intradermal reading of 
this tests is made three to five days afterwards. Patients negative in all the previously referred test, are 
subjected to DPT (5, 12, 20).  
While skin testing is an effective test to evaluate IgE-mediated reactions, the sensitivity of these 
in vivo tests is low in the context of non-immediate allergic reactions, meaning that DPT may be required 
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to establish the diagnosis (5, 12, 20). Moreover, in vitro tests such as BAT, LTT, LAT and enzyme-
linked immunospot have not been completely validated in studies with large samples of patients, 
requiring further validation until their complete usefulness can be properly evaluated (5, 12, 20). 
Cephalosporins 
 
Cephalosporins are antibiotics chemically structured by a β -lactam ring bound to a six-
membered dihydrothiazine ring. Furthermore, cephalosporins have a side chain in C7 and different 
substitutions in C3 position (17, 18). 
In opposition to penicillins, the immunochemistry of cephalosporins is not completely 
understood. Nevertheless, recent studies revealed that like penicillin, cephalosporins are metabolize into 
a major compound, cephalosporoyl. Although, in contrast with benzylpenicilloyl, cephalosporoyl is 
unstable and suffers rapid fragmentation in the dihydrothiazine (six-membered) ring, leading to the 
formation of new molecules that have no structural similarity to benzylpenicilloyl or to the minor 
determinants. The importance of this data is that cross-reactivity between penicillin and cephalosporins 
is normally not induced by major determinant of penicillin, but by sensitization to fragmentation of the 
side chain (6, 32-34). Therefore, cross-reactivity among penicillin and cephalosporins with similar side 
chain can occur in > 30%, and be reduced to less than 10 % if no similar side chain (34). 
Cross-reactivity between cephalosporins follows the same logic, meaning that cephalosporins 
with similar side chain are more likely to present cross-reactivity. However, there are cases where there 
is only selective reaction to one cephalosporin, leading to the conclusion that in this case the reaction be 
mediated to allergic response to the culprit cephalosporin in question (34). 
In regards to the diagnose of cephalosporin allergy, the collection of a detailed is fundamental to 
elicit the suspicion of this process. Confirmation of the diagnose follows similar principles between all 
β-lactam anti-microbials, for both immediate and non-immediate reactions (12, 32-35).  
Nevertheless, while skin testing is an effective test to evaluate IgE-mediated reactions, most of 
the appropriate antigens has not been identified for most drugs. Meaning that apart from penicillin, there 
are no valid in vivo or in vitro diagnostic reagents available for identifying most antibiotic-specific IgE 
antibodies (2). Consequently, in skin tests frequently the whole antibiotics are used, diluted in saline 
solution (12, 32-35). Moreover, skin test must also contain penicillin derivatives (PPL, MDM and AX), 
so to determine if the reaction was caused by elements also present in penicillins (β -lactam ring or 
similar side chain) (34, 36) . 
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Carbapenems, monobactams and clavulanic acid 
 
Carbapenems are chemically similar to penicillin, being formed by a β -lactam ring connected to 
a five-membered ring and two variable chains. However, they contrast with penicillin by the absence of 
sulphur atom in the five-membered ring and by the substitution of the nitrogen in position R1 for a 
carbon. Monobactams constitute a separate group of β -lactam antibiotics, since they are formed by only 
a β -lactam ring, being only effective against gram-negative bacteria. Clavulanic acid are compounds 
that chemically resemble β -lactam molecules, but they have weak antibacterial activity, instead acting 
has inhibitors to β-lactamases (17, 18).   
Carbapenems immunochemistry has not been entirely clarified. These compounds are 
metabolized into a main molecule, carbapenoyl, structurally comparable to benzylpenicilloyl and also 
capable to induce sensitization (6). Because of their biochemical similarities, initially was expected that 
cross-reactivity between penicillins and carbapenems would be high. Early studies reported cross-
sensitization between penicillin allergic patients to carbapenems in the order of nearly 50% (37). 
However, more recent prospective studies have revealed that the risk of cross-ractivity to carbapenems 
in patients with IgE-mediated reaction to penicillin is very low (1%) (38, 39). In the case of non-
immediate reactions to penicillins studies report a prevalence of cross-reactivity to carbapenems between 
0 - 5.5% (40, 41). In summary, cross-reactivity is inferior to what was initially considered and therefore 
carbapenems should not be completely avoided (42).  
About the immunochemistry of monobactams, these compounds are not processed into structures 
chemically resembling penicilloyl acids or minor determinants of penicillin allergy (6).  Thus, 
immunological cross-reactivity does not occur with this agent (43-46). Nevertheless, cross-reactivity 
between aztreonam and ceftazidime has been reported due to side chain homology, yet it is still a rare 
phenomenon (47). Consequently, aztreonam is largely tolerated in patients with confirmed 
hypersensitivity reactions to β-lactams, granting that rarely cross-sensitization can happen with 
ceftazidime (5).  
Finally, clavulanic acid (CLV) has been reported to be responsible for immediate hypersensitivity 
reaction in patients with IgE-mediated allergic reactions to AX-CLV (48, 49). Accordingly, 
hypersensitivity to CLV should be evaluated in cases of allergy to AX-CLV, specifically in situations of 
negative results to AX separately (5). 
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Non β-lactams antimicrobials 
 
In the evaluation of potentially hypersensitivity reactions to non β-lactams antibiotics, the 
diagnostic procedure follows a similar logistics. However, they are being separately considered because 
the diagnostic tests have been mainly validated for β-lactams antibiotics (12).  According to Mirakian et 
al (50) and Romano et al (12), assessment of this patients should begin with the collection of a careful 
clinical history. If the suspicion of an immunological aetiology is considerate, the distinction between 
immediate non-immediate hypersensitivity must be made. In case of immediate hypersensitivity, skin 
testing with SPT and IDT should be considered. If both are negative, DPT can be used to clarify possible 
allergic reaction. On the other hand, in non-immediate hypersensitivity patch test and/or delayed reading 
intradermal test should be used. If both are negative, DPT can be used to clarify possible non IgE 
mediated allergic reaction. 
Macrolides 
 
Macrolides are a group of chemically related antibiotics that are characterized by a macrocyclic 
lactone ring to which are attached one or more deoxy sugars (17, 18). Allergic reactions to these 
antibiotics are unusual occurring in 0.4%-3% of treatments (51). Clinical manifestations of 
hypersensitivity reactions to these antibiotics include urticaria, angioedema, rhino conjunctivitis, 
anaphylaxis (IgE mediated); maculopapular rash, SJS and TEN (1, 2, 12). 
In the diagnose of macrolide allergy, the immunochemistry is not known. Consequently, skin 
testing is made with the use of non-irritating concentrations of the antibiotics (0.05 mg/mL for 
erythromycin, 0.01 mg/mL azithromycin according to a study by Empedrad et al (52); 0.5 mg/ml for 
clarithromycin in a study Mori et al (53)). In the study by Seitz et al (54), all the 53 patients with 
immediate suspected reactions, were skin test and DPT negative, and of the 72 patients with history of 
non-immediate reactions solely one was skin test positive. Mori et al (53), reported that the sensitivity 
and specificity of skin tests in the diagnosis of clarithromycin allergy was of 75% and 90%, respectively. 
Therefore, the significance of skin testing in evaluation of macrolide hypersensitivity is still unknown 
and DPT is frequently required to confirm diagnosis. 
Lastly, macrolides with a 14-membered lactone ring (erythromycin, clarithromycin and 
roxithromycin) have been reported to express cross-reactivity in single cases reports. Moreover, 
azithromycin, a 15-membered lactone ring semisynthetic derivate of erythromycin, cross-reactivity with 
erythromycin has also been described. Nevertheless, there is insufficient evidence to clearly support a 
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common sensitization between macrolides antibiotics. Thus, individual macrolides are generally well 
tolerated (12).   
Tetracyclines 
 
Tetracycline antibiotics are a group of chemically related antimicrobial substances, that share a 
octahydrotetracene-2-carboxamide skeleton, in other words a tetra hydrocarbon ring structure (17, 18). 
This antibiotic class has been reported to cause allergic reactions expressed as urticaria, angioedema, 
anaphylaxis, pericarditis, polyarthralgia, exacerbation of systemic lupus erythematosus, pulmonary 
infiltrates with eosinophilia, photosensitivity, photo-onycholysis, SJS, TEN and DRESS (1, 2, 55-58).  
Minocycline has been reported to induce serious hypersensitivity reactions, such as SJS, DRESS, 
anaphylactic shock, serum sickness and drug-induced lupus. These symptoms normally arise within 4 
weeks of therapy, except for minocycline-induced lupus that typically expresses itself 2 years after the 
initiation of therapy. Hypersensitivity reactions to doxycycline and tetracycline are relatively rare, being 
the photodermatoses and photo-onycholysis the most common (1). 
Clindamycin 
 
Clindamycin is a synthetic derivate of lincomycin (17, 18). This antibiotic has been reported to 
be associated with immediate hypersensitivity, but more frequently with non-immediate reactions 
(described to happen in a rate of between less than 1% to 10.5% of treated subjects), such as 
maculopapular exanthemas, TEN, SJS, AGEP and DRESS (59, 60). The importance of skin testing in 
the evaluation of delayed or non-immediate reactions is datable. Seitz et al (60), retrospectively studied 
clindamycin skin allergy testing in 33 patients with reported history of  non-immediate reactions to 
clindamycin. From his analysis, a rate of positive testing of 15% was observed, as well as a 14.3% of 
false negatives results, posteriorly confirmed by DPT. Similarly, Pereira et al (59), presents a rate of 
positive testing of 30%. Therefore, DPT remains the gold standard for confirmation of the diagnosis of 
clindamycin allergy. However, because of the risk of severe complication inherent to this test, skin 
testing is used to select patients and reduce the number of DPT complications 
Fluoroquinolone 
 
Fluoroquinolones are synthetic fluorinated analogues of nalidixic acid. These antibiotics can be 
further divided in function of their generation: first (cinoxacin and nalidixic acid), second (ofloxacin, 
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norfloxacin, ciprofloxacin, and enoxacin), third (levofloxacin), and fourth (gemifloxacin and 
moxifloxacin) (17, 18). 
Fluoroquinolones have been reported to be associated with immediate and non-immediate 
allergic reactions. Maculopapular rash is the most frequent clinical symptom. Studies report 
moxifloxacin has the fluoroquinolone associated with the highest rate of hypersensitivity reactions (61, 
62). 
The usefulness of skin testing in evaluation of hypersensitivity to quinolones is debatable. Seitz 
et al (63), assessed 64 patients with suspected immediate hypersensitivity. Three of six patients with 
positive result to skin testing were negative, when tested with DPT, as well as three of the forty-two 
patients negative to skin testing, were positive to DPT. Consequently, skin testing generated a sensitivity 
of 50 %, specificity of 93 %, PPV of 50 % and NPV of 93 %. Venturini et al. (64), reported a 5% rate 
of false negative skin tests and only half the subjects with positive skin tests had a positive DPT. 
Uyttebroek et al (65), reported moxifloxacin skin test to have a sensitivity and specificity of 57% and 
12.5%, respectively. 
This alerts to the fact skin testing can produce false positive results. This has been attributed to 
the inherent ability of fluoroquinolones to induce degranulation and release of histamine (66). Therefore, 
DPT remains the gold standard in the diagnostic of hypersensitivity to fluoroquinolones. 
Regarding cross-reactivity amongst fluoroquinolones, these have been reported more frequently 
between first and second generation quinolones. However, cross-reactivity with third and fourth 
generations is more complex. Patients with hypersensitivity to moxifloxacin tolerated ciprofloxacin, but 
patients with allergic reaction to ciprofloxacin responded to moxifloxacin (67). In conclusion, cross-
reactivity in this class is unpredictable and in case of hypersensitivity to this class, different antibiotic 
class should be used.  
Aminoglycosides 
 
Aminoglycosides consist of two or more amino sugars joined in glycosidic linkage to a hexose 
nucleus (17, 18). These antibiotics can be further divided into two groups: the streptidine group (eg, 
streptomycin) and the desoxystreptamine group (eg, kanamycin, amikacin, gentamicin, tobramycin, and 
neomycin). 
Immediate and non-immediate allergic reactions have been reported to aminoglycosides, being 
the latter the most frequent. Of the non-immediate hypersensitivity reactions, the most frequently 
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reported is contact dermatitis, but maculopapular rash, TEN and DRESS, have also been reported. 
Neomycin has been indicated has the aminoglycoside, with the highest rate of hypersensitivity reactions 
(12). 
Because the immunochemistry of aminoglycoside antibiotic allergy is not fully understood, skin 
testing uses native antibiotic. Since the culprit native drug may not contain all the pertinent antigenic 
determinants, false negatives may arise. Therefore, diagnosis confirmation might need DPT (12). 
Regarding cross-reactivity, common sensitization amongst aminoglycosides of the the 
desoxystreptamine group reaches at least 50%, according to Romano et al (12). However, cross-
reactivity between the desoxystreptamine group and streptomycin has not been reported. It is considered 
that this is due to the different chemical structure of streptomycin, which produces different antigenic 
determinants compared to the other aminoglycosides. Therefore, transition between the streptidine group 
and the desoxystreptamine group, can be made safely, when hypersensitivity is reported. 
Sulfonamides 
 
Sulfonamides are sulfonyl arylamines, characterized by a sulfonamide (SO2-NH2) moiety 
directly attached to a benzene ring, which carries an unsubstituted amine (-NH2) at the N4 position (68). 
Sulfonamides antibiotics can induce immediate and non-immediate reactions, being the latter the most 
frequent. Non-immediate reactions can range between maculopapular rashes, to serious complications 
such as TEN, SJS and DRESS. In fact, sulfonamide antibiotic are associated with the highest risk of 
SJS-TEN, when compared to other antibiots (12). 
Two details must be highlighted. Firstly, allergic reactions to sulfonamide antibiotics arise in two 
to four percent of patients treated, but the prevalence rate rises to 50-60% in HIV infected patients. 
Secondly, immunological mediated reactions between different sulphonamides antibiotics have been 
described, because the reactions is directed against the sulfonyl arylamines (68). Therefore, extension of 
the allergic reactions to sulphonamides compounds that are not sulfanilamides, such as celecoxib, 
furosemide, topiramate, has not been reported. Nevertheless, there is an exception, sulfasalazine, 
because this compound used in the treatment of rheumatoid arthritis, is metabolized to sulfapyridine, a 
sulfanilamides (68, 69). 
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Glycopeptides 
 
Vancomycin has been reported to induce allergic reactions such as anaphylaxis, drug fever, 
eosinophilia, skin eruptions (including exfoliative dermatitis), SJS, TEN and vasculitis, but these 
manifestations are rare (1, 12, 70). The most common manifestation is the “red man syndrome”, 
characterized by flushing, warmth, pruritus, and hypotension. This syndrome results of the stimulation 
of histamine release from mast cells derivated of rapid intravenous administration (1, 12, 70). 
Teicoplanin, another glycopeptide antimicrobial, can produce hypersensitivity reactions similar to those 
reported above. However, in opposition to vancomycin, it has less side effects and infrequently produces 
“red man syndrome”, since this antibiotic thus not induce mast cell histamine release. Cross-reactivity 
between this two antibiotics is complex, since some reports express common allergic reaction (71, 72), 
while others refer tolerability between them (73). 
Management and Treatment 
 
The management of antimicrobial hypersensitivity beings with the collection of a complete 
clinical history and identification of a possible relation between the adverse effects and the administered 
pharmaceutical compound. After this, confirmation of the diagnosis should follow the principles 
discussed above. If a positive result is obtained and hypersensitivity is diagnosed, the adequate approach 
to this patient will vary according to the type of allergic reaction presented by the patient. 
Immediate hypersensitivity 
 
In the case of immediate or IgE-mediated hypersensitivity, management and treatment should 
follow: avoidance of the suspected drug, with the application of an alternative compound and, if 
adequate, allergic evaluation of this substance. Nevertheless, if the antimicrobial is fundamental to the 
treatment of the subject or an alternative medication is not available, then desensitization can be tried 
(5, 50). 
Desensitization 
 
Desensitization is defined as the induction of a state of temporary unresponsiveness to a 
compound responsible for a type I or IgE-mediated hypersensitivity reaction (74). After cessation of the 
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drug, tolerability to the pharmaceutical agent is lost in 24-36h hours and if new administration of the 
compound is necessary, desensitization is required (5, 50, 74).  
The mechanism by which this state is obtained is not completely understood. However, it is 
considered that mast cells and basophils are the cellular targets of this process, in which sub-therapeutic 
doses reduce the membrane expression of IgE and cause the cell to be unresponsive (1, 5, 50, 74). 
This procedure consists of the administration of increasing doses of the antimicrobial agent, 
during a period of several hours, until the pretended therapeutical dose is obtained (1, 2, 5, 50, 74). Initial 
dose 1/10 000 to 1/100 of the full therapeutic one and this are doubled every 15 to 30 minutes. The drug 
can be administrated orally or intravenously, but oral route has been reported to have less reactions (5, 
50). 
Nevertheless, desensitization can induce allergic reaction in about 1/3 of the patients submitted 
to this procedure. According to Cernadas et al(74), the great majority of this are mild reactions (90%), 
which can be treated with simple cessation of the drug. Then, new sensitization can be tried from the 
last tolerated dose, since these reactions are most frequent on the first desensitization. However, if severe 
reaction occurs (AGEP, SJS, TEN, etc), then desensitization is contraindicated. Desensitization success 
has been reported to be range between 58%-100% (75). 
Non-Immediate hypersensitivity 
 
In the case of delayed hypersensitivity, avoidance of the drug and allergic evaluation of 
alternative compound, if appropriate, is the correct clinical approach (5, 50). Although desensitization 
was designed for immediate reactions, the procedure has been reported to be successful in non-
immediate allergic reactions, and protocols are available for several β-lactams and non-β antibiotics. 
Though, until now no controlled clinical trials are available, most of the documented cases do not include 
previous confirmation of the diagnosis with full allergic evaluation, and the pathophysiology is largely 
unknown (76). Therefore, further considerations and research must be made is this area. 
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Discussion 
 
Adverse events related to the use of antimicrobial agents are commonly reported. Amongst the 
great myriad of symptoms and signs, only a smaller group of adverse reactions are immunologically 
mediated and correspond to true hypersensitivity reactions. Therefore, it is fundamentally important that 
a detailed medical history and physical examination are conducted in order to help the physician to 
differentiate between drug adverse reactions and hypersensitivity. 
In the presence of a high suspicion of an allergic reaction, it stands logical the need for the 
execution of a confirmatory diagnostic test. Although, in vitro tests have shown promising results, they 
have not been fully validated in large samples studies. Meaning that in vivo tests are the unique auxiliary 
resource available for the confirmation of diagnosis, namely skin prick tests, patch tests, and DPTs.  
Skin tests have unsatisfactory low rates of sensitivity, specificity and predictive negative and positive 
values, more so when used outside the context of immediate hypersensitivity reactions to β-lactams. On 
the other hand, DPT are the gold standard diagnostic test, with very high negative predictive value, but 
are associated with the potential risk of severe allergic reaction. Therefore, to increase sensitivity in the 
diagnostic process and reduce the risk and number of DPT, a sequential approach of skin test followed 
by DPT is recommended. 
Furthermore, apart from penicillin, the great majority of the appropriate antigens has not been identified 
for most pharmaceuticals agents, implicating the frequent use off whole antibiotics, diluted in saline 
solution, for the preparations in skin tests. This can lead to an important number of false negatives results 
for reasons such as the antigenic agent might be a metabolite of the drug not produced from skin 
application; or concentration or vehicle used might not be adequate. Consequently, further research must 
be conducted in this area, in order to develop the comprehension on the immunochemistry processes 
involved in the mediation of hypersensitivity to non-penicillin antibiotics.    
On the other hand, the majority of allergies to penicillin are determined by benzylpenicilloyl, and in a 
minor significance, to the minor determinants (penilloate, penicilloate and specific metabolite side chain 
derivatives). Therefore, cross-reactivity between penicillins and other β-lactam antimicrobials are 
determined by unique metabolites or side-chain determinants. Consequently, for patients allergic to 
penicillin, the alternative use of another β-lactam antimicrobials, namely a cephalosporin with side 
chains that differ from penicillin or amoxicillin, is associated with a low risk off cross-reactivity and 
their use is defensible by available evidence. 
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Regarding non β-lactam antimicrobials, evidence suggests that every antibiotics class has its own 
particularities. Cross-reactivity amongst antibiotics of the same class is not linear and individual 
considerations should be made in the treatment of patients presenting with hypersensitivity reactions, 
considering the antibiotic used, but also the disease being treated and immunological state of the patient. 
Desensitization is a valid approach in the management of patients with IgE mediated hypersensitivity 
reactions, in cases where the culprit drug is fundamental for the treatment. Nevertheless, although only 
in the minority of cases, desensitization can induce severe allergic reactions. Therefore, this process 
must be executed in an appropriate environment and by trained professionals. Moreover, is 
contraindicated in patients presenting with severe reactions. Although desensitization was designed for 
immediate reactions, the procedure has been reported to be successful in non-immediate allergic 
reactions, and protocols are available for several β-lactams and non-β antibiotics. Nonetheless, until now 
no controlled clinical trials are available, most of the documented cases do not include previous 
confirmation of the diagnosis with full allergic evaluation, and the pathophysiology is largely unknown. 
Therefore, further considerations and research must be made is this area. 
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Conclusion 
 
Antibiotics are one of the drugs most commonly associated with allergic events, ranging from 
mild symptoms to severe life-threating reactions. However, this are often mistaken with adverse events 
associated with the therapeutical use of this drugs. Therefore, a careful clinical history is required to 
determined true allergic reactions, from adverse reactions, and avoid the over diagnose of antibiotic 
allergy, associated with increased incidence of antimicrobial resistance and medical costs.  
If a high suspicion of hypersensitivity reaction exists, then a full allergic evaluation should be 
made to confirm diagnosis. The work up follows specific considerations in function of the type of 
allergic reaction presented. Nevertheless, with the exception of β-lactam antimicrobials, not only 
immunological mechanisms are not fully understood, but also the sensitivity and specificity of the 
diagnostic procedures are lower than desirable. Therefore, further investigation in this area is needed. 
After confirmation of the diagnosis of allergic reaction, the management of this patients should 
follow avoidance and application of an alternative tolerated drug. If the drug in question is indispensable 
for the treatment of the patient, then desensitization can be tried. However, once again, for non-
immediate reactions, for non β-lactam antimicrobials, more research is required to further validated this 
approach. 
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